Home › Encyclopedia › Thymopentin: Research Status and Trial Data
Research / Unapproved

Thymopentin: Research Status and Trial Data

Drafted by an automated content engine from FDA, PubChem, ClinicalTrials.gov, NIH DSLD, and Open Beauty Facts data.

Molecular formulaC30H49N9O9
Molecular weight679.8 g/mol
Registered trials12
PubChem CID451417

Thymopentin shows up in searches tied to immune research, but it has no approved prescription label in the United States. Anyone researching it should understand what is actually documented versus what remains unproven.

Regulatory Status

Thymopentin is classified as an unapproved research compound. No FDA-approved label, brand name, or indication exists for it, and the data reviewed here does not include labeling information.

What Thymopentin Is

Thymopentin is a synthetic peptide with the molecular formula C30H49N9O9 and a molecular weight of about 679.8. It is cataloged in PubChem under CID 451417, which provides its structural and chemical reference data. Beyond this chemical identity, no approved pharmacological description is available.

Trial Landscape

Registered records show 12 clinical trials associated with thymopentin. One identified study, a double blind trial examining thymopentin's effects in patients with HIV-1 infection, is listed as completed. The available trial sample does not establish that thymopentin is effective or safe for any condition, and results from individual studies should not be generalized.

FAQ

Is thymopentin FDA approved?
No. Thymopentin does not have an FDA-approved label, brand name, or approved indication. It is classified as an unapproved research compound.
What is thymopentin chemically?
Thymopentin is a synthetic peptide with the molecular formula C30H49N9O9 and a molecular weight of approximately 679.8. It is indexed in PubChem under CID 451417 for reference purposes.
How many clinical trials have studied thymopentin?
Public trial registries list 12 clinical trials associated with thymopentin. These trials vary in focus and status, and their existence does not confirm any approved use.
What did the completed thymopentin trial examine?
One completed double blind study examined thymopentin's effects in patients with HIV-1 infection. This single trial does not establish efficacy or safety for that or any other condition.
Are there reported side effects for thymopentin?
No adverse event report data was available for thymopentin at the time this monograph was compiled, so no side effect pattern can be summarized.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication. Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.

Sources: PubChem ClinicalTrials.gov

Updated 2026-08-04